https://charts.traderzeitung.de/phases/US68218J1034 string(1420) "{"isin":"US68218J1034","name":"OmniAb Inc","stock_id_xnas":27073133,"stock_id_xnys":null,"generated_at":"2026-09-24 01:31:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.58,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":4.58,"close_at":"2026-09-21 22:00:00","complete":true,"perf_pct":0}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.93,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":7.6419},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":4.88,"close_at":"2026-09-22 22:39:00","complete":true,"perf_pct":-1.0142}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.78,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-2.0492},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

OmniAb Aktie News & Nachrichten

[WKN: A3DZDL | Symbol: OABI]

Realtimekurs

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über OmniAb gefunden werden.

OmniAb Nachrichtenticker öffnen

MT Newswires 17.08.2026 22:03 Uhr

OmniAb Aktie News & Nachrichten

Artikel aus der Redaktion der Trader-Zeitung

Sektor-Update: Gesundheitsaktien am späten Nachmittag schwächer

Sektor-Update: Gesundheitswesen

Größte Gewinner am Mittag

Größte Gewinner vorbörslich

OmniAb geht globale Zusammenarbeit mit Eli Lilly für Ionenkanal-Programm ein; hebt Ganzjahres-Bargeldaussichten an

Research-Alert: Veraxa Biotech treibt Programm für bispezifische Antikörper-Wirkstoff-Konjugate voran

OmniAb ernennt Amechi Nwachuku zum Chief Operating Officer